PF-562271 besylate，PF-562271的苯磺酸盐，是可口服的、ATP竞争型的、可逆的FAK抑制剂，IC₅₀为1.5 nM，作用于FAK比作用于Pyk2 (IC₅₀: 13 nM)选择性高10倍左右，具有潜在的抗肿瘤和抗血管生成活性。

参考文献

[1] Roberts WG, Ung E, Whalen P, et al. Antitumor activity and pharmacology of a selective focal adhesion kinase inhibitor, PF-562,271. Cancer Res. 2008 Mar 15;68(6):1935-44. doi: 10.1158/0008-5472.CAN-07-5155(IF:8.378).

[2] Sun H, Pisle S, Gardner ER, et al. Bioluminescent imaging study: FAK inhibitor, PF-562,271, preclinical study in PC3M-luc-C6 local implant and metastasis xenograft models. Cancer Biol Ther. 2010 Jul 1;10(1):38-43. doi: 10.4161/cbt.10.1.11993(IF:2.879).

-25~-15℃保存，有效期3年。